Mepsgen launches microfluidics-based nanoparticle system in US for mRNA and gene therapy

Korean biotech Mepsgen, known for its organ-on-a-chip platforms for drug development, has launched its microfluidics-based nanoparticle system NanoCalibur in the U.S., expanding access to what it says is a scalable, reproducible manufacturing tool for lipid nanoparticles and other formats used in mRNA, gene therapy, and targeted drug delivery.

The U.S. launch, announced Wednesday, follows NanoCalibur’s domestic debut in Korea late last year.

Built on a proprietary microvortex mixing system designed to handle small liquid volumes, NanoCalibur offers what Mepsgen describes as tight control over particle synthesis, delivering continuous, low-shear output for sensitive nanoparticle formulations. The system combines feedback-controlled sensors with a closed-loop architecture to ensure consistent performance—even for fragile cargo like mRNA and oligonucleotides.

According to Mepsgen, the system consistently produces particles with a polydispersity index (PDI) under 0.1 and encapsulation efficiency above 95 percent, including for mRNA, for over four weeks—maintaining stable particle size, PDI, and mRNA integrity throughout.

“With its cutting-edge microfluidics technology and user-friendly design, this micro-lab makes it easier for researchers to focus on their mission to develop the next generation of nanoparticle-based therapeutics,” Mepsgen CEO Kim Yong-tae said in a statement.

The system is designed for direct scale-up from bench to GMP production, eliminating the need to reoptimize synthesis protocols. At larger volumes, Mepsgen says it maintains uniformity with no batch-to-batch variation, aided by controlled shear rates that preserve biomolecular structure and function.

Mepsgen will showcase NanoCalibur at the 4th LNP Formulation & Process Development Summit in Boston, April 14-16.